Table 1 Baseline data
Contents | Observation group (n = 11) | Control group (n = 11) |
|---|---|---|
Sex | ||
Male | 11 (100.0%) | 10 (90.9%) |
Female | 0 (0.0%) | 1 (9.1%) |
Age (year) | 24.4 ± 5.0 | 24.9 ± 5.4 |
BMI (kg/m2) | 21.8 ± 3.0 | 19.9 ± 2.6 |
Volume of fat (mL) | 48.4 ± 23.1 | – |
Number of cells (×106cells) | 142.3 ± 45.7 | – |
Simplified CDAI† | 4.3 ± 0.5 | 4.4 ± 0.7 |
PDAI* | 8.5 ± 1.4 | 9.5 ± 1.7 |
IBDQ‡ | 143.5 ± 19.8 | 137.9 ± 29.7 |
VAS§ | 0.8 ± 1.0 | 1.1 ± 1.0 |
Wexner¶ | 1.2 ± 1.3 | 1.5 ± 0.7 |
Location of Crohn’s disease | ||
Ileum (L1) | 1 (9.1%) | 1 (9.1%) |
Colon (L2) | 4 (36.4%) | 3 (27.3%) |
Ileocolon (L3) | 6 (54.6%) | 7 (63.6%) |
Upper gastrointestinal (L4) | 0 (0.0%) | 0 (0.0%) |
Classification of fistula-in-ano (Parks) | ||
Transsphincteric | 4 (36.4%) | 7 (63.6%) |
Suprasphincteric | 1 (9.1%) | 0 (0.0%) |
Intersphincteric | 4 (36.4%) | 3 (27.3%) |
Extrasphincteric | 2 (18.2%) | 1 (9.1%) |
Number of internal openings | ||
1 | 9 (81.8%) | 10 (90.9%) |
2 | 2 (18.2%) | 1 (9.1%) |
Number of external openings | ||
1 | 5 (45.4%) | 5 (45.4%) |
2 | 3 (27.3%) | 4 (36.4%) |
3 | 2 (18.2%) | 2 (18.2%) |
4 | 1 (9.1%) | 0 (0.0%) |
Drug use at baseline | ||
ASA | 11/11 (100.0%) | 11/11 (100.0%) |
Probiotics | 11/11 (100.0%) | 11/11 (100.0%) |
Immunomodulators | 1/11 (9.1%) | 3/11 (27.3%) |
Antibiotics | 1/11 (9.1%) | 1/11 (9.1%) |
Anti-TNF | 0/11 (0.0%) | 0/11 (0.0%) |
Glucocorticoids | 0/11 (0.0%) | 0/11 (0.0%) |